We are live on
!
Find out more
Aberdeen Group Portfolio holdings
AUM
$61.9B
1-Year Est. Return
29.81%
This Fund
S&P 500
This Quarter
Est. Return
+5.07%
1 Year Est. Return
+29.81%
3 Year Est. Return
+93.17%
5 Year Est. Return
+119.65%
10 Year Est. Return
–
AUM
$64.6B
AUM Growth
+$1.37B
(+2.2%)
Cap. Flow
-$686M
Cap. Flow
% of AUM
-1.06%
Top 10 Holdings %
Top 10 Hldgs %
38.17%
Holding
995
New
43
Increased
362
Reduced
491
Closed
59
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nu Holdings
NU
|
+$36.3M |
| 2 |
SCHW
Charles Schwab
SCHW
|
+$36.1M |
| 3 |
Ascendis Pharma A/S
ASND
|
+$35.6M |
| 4 |
Danaher
DHR
|
+$30.5M |
| 5 |
uniQure
QURE
|
+$28.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$93.5M |
| 2 |
Mercado Libre
MELI
|
+$86M |
| 3 |
Microsoft
MSFT
|
+$62.9M |
| 4 |
Apple
AAPL
|
+$55.6M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
+$48.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32.59% |
| 2 | Healthcare | 13.39% |
| 3 | Consumer Discretionary | 11.41% |
| 4 | Communication Services | 11.25% |
| 5 | Financials | 10.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
726
Lucid Diagnostics
LUCD
$175M
| $3.77M | 0.01% |
3,457,894
+957,894
| +38% | +$1.07M |
|
727
NetEase
NTES
$83B
| $3.67M | 0.01% |
26,682
+6,317
| +31% | +$897K |
|
728
Equillium
EQ
$144M
| $3.67M | 0.01% |
2,366,688
+1,987,162
| +524% | +$2.42M |
|
729
Petrobras Class A
PBR.A
$106B
| $3.63M | 0.01% |
321,850
+101,582
| +46% | +$1.17M |
|
730
iShares MSCI Taiwan ETF
EWT
$9.13B
| $3.57M | 0.01% |
+56,229
| New | +$3.62M |
|
731
Manhattan Associates
MANH
$11.9B
| $3.56M | 0.01% |
20,537
-1,249
| -6% | -$228K |
|
732
National Health Investors
NHI
$3.79B
| $3.46M | 0.01% |
45,355
+19,241
| +74% | +$1.48M |
|
733
EastGroup Properties
EGP
$11.2B
| $3.41M | 0.01% |
19,142
-2,070
| -10% | -$368K |
|
734
Agree Realty
ADC
$9.66B
| $3.31M | 0.01% |
45,976
+8,974
| +24% | +$656K |
|
735
Rexford Industrial Realty
REXR
$8.63B
| $3.27M | 0.01% |
84,439
-4,444
| -5% | -$183K |
|
736
Integer Holdings
ITGR
$3.39B
| $3.26M | 0.01% |
41,546
-249,563
| -86% | -$19.9M |
|
737
Tencent Music
TME
$15.9B
| $3.26M | 0.01% |
185,796
-190
| -0.1% | -$3.85K |
|
738
CareTrust REIT
CTRE
$10B
| $3.25M | 0.01% |
89,948
+5,124
| +6% | +$184K |
|
739
Abeona Therapeutics
ABEO
$355M
| $3.25M | 0.01% |
+616,413
| New | +$3.1M |
|
740
Invesco QQQ Trust
QQQ
$436B
| $3.22M | 0.01% |
5,243
+1,567
| +43% | +$962K |
|
741
Grupo Aeroportuario del Sureste
ASR
$8.16B
| $2.94M | ﹤0.01% |
+9,084
| New | +$2.81M |
|
742
Infosys
INFY
$51B
| $2.92M | ﹤0.01% |
163,675
-146,466
| -47% | -$2.53M |
|
743
Allogene Therapeutics
ALLO
$625M
| $2.86M | ﹤0.01% |
2,086,332
+504,067
| +32% | +$665K |
|
744
STAG Industrial
STAG
$7.5B
| $2.86M | ﹤0.01% |
77,694
+3,521
| +5% | +$134K |
|
745
Brown-Forman Class B
BF.B
$13.5B
| $2.84M | ﹤0.01% |
108,898
-15,182
| -12% | -$427K |
|
746
News Corp Class B
NWS
$17.7B
| $2.82M | ﹤0.01% |
95,234
-2,949
| -3% | -$87.9K |
|
747
HEICO Corp
HEI
$49.6B
| $2.82M | ﹤0.01% |
8,702
-224
| -3% | -$70.8K |
|
748
DigitalBridge
DBRG
$2.92B
| $2.77M | ﹤0.01% |
180,352
-102,880
| -36% | -$1.24M |
|
749
Qfin Holdings
QFIN
$1.68B
| $2.74M | ﹤0.01% |
142,433
-16,733
| -11% | -$376K |
|
750
Apogee Therapeutics
APGE
$10.1B
| $2.73M | ﹤0.01% |
36,103
-18,657
| -34% | -$1.18M |
|
Similar funds
Aberdeen Group's Q4 2025 Portfolio in Review
As of Q4 2025, Aberdeen Group held 995 positions worth $64.6B, up 2.2% from $63.2B the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Aberdeen Group's Q4 2025 filing shows 43 new, 362 increased, 491 reduced and 59 closed positions. Its largest new stake was Praxis Precision Medicines: 134,992 shares worth $39.8M. The largest sale was Eli Lilly, an estimated $93.5M.
By sector, the portfolio is most concentrated in Technology at 33% of assets, down from 33% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Aberdeen Group's largest Q4 2025 buy was Praxis Precision Medicines: 134,992 shares worth $39.8M.
- Aberdeen Group added most to Nu Holdings in Q4 2025, an estimated $36.3M increase.
- Aberdeen Group's biggest Q4 2025 reduction was Eli Lilly, cutting an estimated $93.5M.
- Aberdeen Group fully exited BioMarin Pharmaceuticals in Q4 2025, selling an estimated $48.9M.
- Aberdeen Group's ten largest holdings make up 38% of its $64.6B portfolio in Q4 2025.
- Aberdeen Group opened 43 new positions and closed 59 in Q4 2025.
- Aberdeen Group's portfolio value rose 2.2% quarter-over-quarter to $64.6B.
Based on Aberdeen Group's 13F filing for Q4 2025, filed 16 Jan 2026.